Last checked at 30 Nov 2022 07:00
LungLife AI, Inc. (the "Company" or "LungLife")
Total Voting Rights
The Company's total issued share capital consists of 25,485,982 Ordinary Shares of US $0.0001 each ("Ordinary Shares") with one voting right per Ordinary Share. There are no Ordinary Shares held in treasury. The total number of voting rights in the Company is therefore 25,485,982. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
LungLife AI, Inc. | www.lunglifeai.com |
Paul Pagano, CEO | Via Walbrook PR |
David Anderson, CFO |
|
|
|
Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
Daniel Adams / Virginia Bull / Cameron MacRitchie | |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
Paul McManus / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654/ 07867 984 082 |
About LungLife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com